Sylke Maas | Vice President, Investor Relations |
Ugur Sahin | Chief Executive Officer and Co-Founder |
Sean Marett | Chief Business and Commercial Officer |
Ozlem Tureci | Chief Medical Officer and Co-Founder |
Sierk Poetting | Chief Financial and Operating Officer |
Ryan Richardson | Chief Strategy Officer |
Tazeen Ahmad | Bank of America |
Cory Kasimov | JP Morgan |
Daina Graybosch | SVB Leerink |
Navin Jacob | UBS |
Akash Tewari | Wolfe Research |
Arlinda Lee | Canaccord |
Zhiqiang Shu | Berenberg |
Daniel Wendorff | Commerzbank |
Olga Smolentseva | Bryan, Garnier & Co |
Good morning, and good afternoon. Thank you for joining us today to review BioNTech's third-quarter 2020 operational progress and financial results.
Before we start, we encourage you to view the slides for this webcast, as well as the operational and financial results, press release issued this morning, both of which are accessible on our website in the Investors section.
As shown on Slide 2, during today's presentation, we will be making several forward-looking statements. These forward-looking statements include, but are not limited to, BioNTech's efforts to combat COVID-19; the potential safety and efficacy of BNT162; the timing for submission of data for, or receipt of, or potential approval or Emergency Use Authorization with respect to our BNT162 program; the ability of BioNTech to supply BNT162; the planned next steps in BioNTech's pipeline programs; the timing for enrollment initiation, completion and reporting of data from our clinical trials; and BioNTech's anticipated cash usage for fiscal-year 2020 and beyond.